Latest studies
- RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking at a new medicine called Vyvgart for people with Thyroid Eye Disease. It aims to see if the medicine can help reduce bulging eyes and improve eye health, compared to a dummy medicine, over 24 weeks.
Thyroid Eye Disease (TED)Latvia - Enrolling by invitationNA
Optical Coherence Tomography in Acute Vessel Evaluation
This study compares two ways to help people having a heart attack: one uses standard X-rays, the other uses a special camera called OCT. We want to see if the OCT camera leads to better results for patients.
Ischemic Heart DiseaseIschemic Coronary Artery DiseaseACS (Acute Coronary Syndrome)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
This study looks at a new version of Eylea (a medicine for eye problems) to see if it's safe and works well for people with blurry vision caused by fluid build-up at the back of their eye. It compares the new version to the standard treatment.
Macular edema secondary to retinal vein occlusionLatvia - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisLatvia - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
Non-small Cell Lung CancerLatvia - Active not recruitingPHASE3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study looks at a new drug, astegolimab, for people with COPD who have flare-ups often. It compares the new drug to a dummy treatment (placebo) to see if it's safe and helps improve their breathing and reduce flare-ups.
Chronic Obstructive Pulmonary Disease (COPD)Latvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain
This study is testing a new tablet, OG-6219, for women aged 18-49 experiencing moderate to severe pain from endometriosis. It will compare different doses against a dummy pill to see how well it works and if it's safe.
Endometriosis related painLatvia - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
This study is looking at a new medicine, EYE103, for people with a common eye condition called diabetic macular oedema (DME). It compares EYE103 with a standard treatment, ranibizumab, to see if it's safe and helps improve vision.
Diabetic Macular Edema (DME)Latvia - AuthorisedHuman Pharmacology (Phase I)- Other
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
This study is testing a new medicine, TQS-168, for people with Motor Neurone Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS). It's an early-stage trial to see if the medicine is safe, how well the body handles it, and if it shows any signs of helping the condition.
AMYOTROPHIC LATERAL SCLEROSISLatvia - RecruitingPHASE2
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is looking at a new experimental drug, REGN13335, for adults with Pulmonary Arterial Hypertension (PAH). Researchers want to see if it's safe and effective when taken with other PAH medicines.
Pulmonary Arterial Hypertension (PAH)Latvia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
This study looks at a new medicine called sonelokimab for psoriatic arthritis. It checks how safe and helpful the medicine is over a long time for people who have already tried it in another study. Doctors will monitor side effects and overall health.
psoriatic arthritis (PsA)Latvia - Active not recruitingPHASE3
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
This study looks at a new drug called Pegozafermin for people with very high triglyceride levels, a type of fat in the blood. Researchers want to see if this drug can safely lower these levels over 26 weeks compared to a dummy drug.
Severe HypertriglyceridemiaLatvia - Authorised (with conditions)Therapeutic confirmatory (Phase III)
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new drug called masitinib for people with Motor Neurone Disease (ALS). It compares masitinib with a dummy pill (placebo) alongside standard treatment to see if it's safe and helps slow down the disease.
Amyotrophic Lateral SclerosisLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism after Elective, Unilateral, Total Knee Arthroplasty
This study is testing a new medicine called REGN9933 to see if it can prevent blood clots after knee replacement surgery. Blood clots can be serious, so finding good ways to prevent them is important. We're comparing REGN9933 to other common clot-preventing medicines.
Thromboembolic diseaseLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Versus EU-Prolia® in Women with Post- Menopausal Osteoporosis
This study compares a new medicine (BP16) with an existing one (Prolia®) for women with weak bones after menopause. Researchers will check if BP16 helps strengthen bones, how safe it is, and if the body reacts to it, over about a year and a half.
Post-Menopausal OsteoporosisLatvia - Active not recruitingPHASE3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
This study is testing a new medicine, inclisiran, to see if it can prevent serious heart problems like heart attacks and strokes in people who are at high risk but haven't had one before. They are comparing it to a dummy medicine.
Primary Prevention of Atherosclerotic Cardiovascular DiseaseLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study is testing a new inhaled medicine, saralutinib, for people with pulmonary arterial hypertension (PAH). Researchers want to see if it helps patients walk further in six minutes and improves their health compared to a dummy inhaler.
Pulmonary Arterial HypertensionLatvia - AuthorisedTherapeutic use (Phase IV)
An open-label, randomized clinical trial comparing Etacizin versus Propafenone in Atrial Fibrillation
This study compares two medicines, Etacizin and Propafenone, for people with a heart condition called atrial fibrillation. Doctors want to see which medicine is better at keeping the heart's rhythm normal for six months after it has been reset.
Atrial fibrillationLatvia - RecruitingPHASE3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This study is for people with wet macular degeneration, a common eye condition. It's testing a new, single injection treatment (4D-150) against a standard treatment (Eylea) to see if it can help improve or maintain vision. The goal is to find a longer-lasting solution.
Neovascular Age-Related Macular Degeneration (nAMD)Latvia - Active not recruitingPHASE3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
This study is an extension for people in the UK with moderately to severely active ulcerative colitis who have already taken part in a specific etrasimod trial. It aims to gather more information on the long-term safety and effectiveness of etrasimod for this condition.
Ulcerative ColitisLatvia - Active not recruiting
The OPBC-07/microNAC Study
This study looks at whether it's safe to skip a full lymph node removal surgery in breast cancer patients who have only tiny traces of cancer left in their armpit lymph nodes after chemotherapy. It checks how these patients have fared over time.
Breast CancerLatvia - Active not recruitingPHASE3
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is looking at a new medicine called vutrisiran for people with a heart condition called transthyretin amyloidosis (ATTR) cardiomyopathy. It aims to see if the medicine can help improve the condition and if it's safe compared to a dummy treatment.
Transthyretin Amyloidosis (ATTR) With CardiomyopathyLatvia - RecruitingPHASE2
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
This study looks at a new, climate-friendly asthma inhaler. We want to check if it works just as well and is as safe as current inhalers for people with mild to moderate asthma. It's about finding better ways to manage asthma while caring for our planet.
AsthmaLatvia - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
Lung NeoplasmsCarcinoma, Non-Small-Cell LungLatvia - Active not recruitingPHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This study looks at a new drug, efgartigimod, for adults with CIDP, a nerve condition. It aims to see how safe and effective it is over a long time when given under the skin. Some participants might also try taking the drug less often.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Latvia - RecruitingPHASE3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
This study is testing a new medicine, depemokimab, for adults aged 40-80 with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) and a specific type of inflammation. It aims to see if depemokimab improves symptoms and is safe when added to their usual inhaler treatment.
Pulmonary Disease, Chronic ObstructiveLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
This study is testing a new medicine, XEN1101, for people with focal-onset seizures. It aims to see if the drug can reduce the number of seizures people have compared to a dummy pill. This is a large study to make sure the medicine is safe and works well.
Focal Onset SeizuresLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
This study is testing a new medication called asundexian against a standard treatment (apixaban) to see how well it prevents strokes or serious blood clots in people with atrial fibrillation, a type of irregular heartbeat. It's also looking at how safe the new drug is.
Prevention of stroke or systemic embolism in atrial fibrillationLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
This study is looking into a new medication called Tildacerfont for adults with a condition called classic congenital adrenal hyperplasia. It aims to see if Tildacerfont can help reduce the amount of steroid medicine (like hydrocortisone or prednisolone) people need to take.
Classic Congenital Adrenal HyperplasiaLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
Previously Untreated Advanced Gastric or Gastroesophageal JunctionCancer with FGFR2b overexpressionLatvia - Ongoing, recruitingPhase II and Phase III (Integrated)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
This study is looking into a new treatment, AV-101, for Pulmonary Arterial Hypertension (PAH), a condition affecting the lungs and heart. It aims to see if the treatment is safe and effective by comparing it to a dummy medicine.
Pulmonary Arterial Hypertension (PAH)Latvia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months
This study is looking at how safe new vaccines are for babies aged 5 to 23 months. It's testing two different vaccines (mRNA-1345 and mRNA-1365) to see if they help protect against chest infections, like those caused by RSV. Scientists are checking for any side effects and how well the vaccines boost the babies' immune systems.
Acute lower respiratory infectionLatvia - Active not recruitingNA
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
This study is looking at a new type of graft, called the Xeltis aXess graft, for people with kidney failure needing dialysis. It aims to see if it's safe and works well for creating a connection that doctors can use for dialysis treatments.
End-stage Renal DiseaseLatvia - AuthorisedTherapeutic use (Phase IV)
The role of meldonium and individualized physical activities in the treatment of patients with heart failure
This study is looking at how a medication called Meldonium, combined with personalised exercise, might help people in the UK who have a type of heart failure where their heart still pumps blood well but struggles to relax properly. It’s trying to see if this treatment can improve how much exercise they can do.
Chronic heart failure with preserved ejection fractionLatvia - Active not recruitingPHASE3
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
This study is comparing two medicines, milvexian and apixaban, for people with an irregular heartbeat called atrial fibrillation. We want to see if milvexian is just as good as apixaban at stopping serious problems like strokes, which can happen with this condition.
Atrial FibrillationLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This study is looking at a medicine called ozanimod for people with Crohn's disease that is moderate to severe. It wants to see how well the medicine helps reduce their symptoms and improve their gut health over a long period. Researchers will also check how it affects COVID-19 antibody levels.
Moderately to Severely Active Crohn's DiseaseLatvia - Recruiting
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
The RIETE study is building a large database of information from patients with blood clots (venous thromboembolism). It helps doctors better understand and treat patients, especially those with other health problems, to improve care and understand what medicine works best for different groups.
Venous ThromboembolismLatvia - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesLatvia - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesLatvia - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration
This study is testing a new version of an eye medicine, ranibizumab (like Lucentis), for wet age-related macular degeneration. Researchers want to see if the new version works as well and is as safe as the original to help people see better.
wet macula degenerationLatvia - Active not recruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG)
This study is testing a new medicine, Pegozafermin, for people with very high triglyceride levels. We want to see if it lowers these levels and if it's safe to use. Half the participants will get the new medicine and half will get a dummy medicine.
Severe HypertriglyceridemiaLatvia - Enrolling by invitation
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study looks at how HIV affects people in Europe and how treatments work over time. It helps us understand health changes and the impact of new medicines for HIV and related conditions like hepatitis.
HIVHepatitis BHepatitis CAIDSLatvia - Active not recruitingPHASE3
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
This study is looking at a new treatment called efti, combined with standard care, for advanced lung cancer. It compares how well this combination works against the standard care alone to see if it helps people live longer and stops cancer from growing for longer. Participants will receive treatment for up to two years.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Latvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This study is looking at a new medicine called Danicopan for a type of age-related macular degeneration (AMD) called geographic atrophy (GA). Researchers want to see if the medicine can slow down vision loss and the growth of blind spots.
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)Latvia - Active not recruitingPHASE3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
This study is comparing a new medication called remibrutinib with an existing treatment, teriflunomide, for people with relapsing multiple sclerosis (RMS). It aims to see how well remibrutinib works and if it's safe to use in managing RMS symptoms.
Relapsing Multiple SclerosisLatvia - Active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
This study compares a new medicine, risankizumab, with a dummy treatment (placebo) for people with active psoriatic arthritis. It checks how safe and effective risankizumab is, especially for those who haven't responded well to other treatments.
Psoriatic ArthritisLatvia